NASDAQ:CBLL • US15678C1027
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CERIBELL INC (CBLL).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-01-28 | BTIG | Reiterate | Buy -> Buy |
| 2025-12-17 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-12-15 | BTIG | Reiterate | Buy -> Buy |
| 2025-11-05 | TD Cowen | Maintains | Buy -> Buy |
| 2025-11-05 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-10-21 | Raymond James | Initiate | Strong Buy |
| 2025-04-04 | Ladenburg Thalmann | Initiate | Buy |
| 2025-02-26 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-12-09 | TD Cowen | Maintains | Buy -> Buy |
| 2024-12-09 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-11-13 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-11-05 | TD Cowen | Initiate | Buy |
| 2024-11-05 | William Blair | Initiate | Outperform |
| 2024-11-05 | JP Morgan | Initiate | Overweight |
| 2024-11-05 | Canaccord Genuity | Initiate | Buy |
| 2024-11-05 | B of A Securities | Initiate | Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 45.225M 74.47% | 65.444M 44.71% | 89.063M 36.09% | 115.4M 29.57% | 148.22M 28.44% | 189.6M 27.92% | |
| EBITDA YoY % growth | -29.194M 17.82% | -38.568M -32.11% | -57.061M -47.95% | -44.611M 21.82% | -30.688M 31.21% | -24.276M 20.90% | |
| EBIT YoY % growth | -30.041M 16.60% | -39.709M -32.18% | -58.402M -47.07% | -57.401M 1.71% | -42.033M 26.77% | -32.64M 22.35% | |
| Operating Margin | -66.43% | -60.68% | -65.57% | -49.74% | -28.36% | -17.22% | |
| EPS YoY % growth | N/A | N/A | -1.47 34.43% | -1.49 -1.30% | -1.03 31.04% | -0.87 14.91% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | Q4 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.40 -10.50% | -0.40 -4.62% | -0.36 3.03% | -0.33 6.96% | -0.25 36.47% | -0.24 38.74% | -0.24 33.12% | -0.21 37.80% | -0.22 11.20% | -0.22 7.85% | -0.18 23.49% | -0.14 31.46% |
| Revenue Q2Q % growth | 26.61M 29.86% | 27.723M 30.78% | 29.333M 29.86% | 31.734M 28.04% | 34.626M 30.12% | 36.015M 29.91% | 37.73M 28.63% | 41.096M 29.50% | 44.778M 29.32% | 46.736M 29.77% | 49.511M 31.22% | 54.162M 31.79% |
| EBITDA Q2Q % growth | -14.263M -2.82% | -14.623M -2.31% | -13.097M 3.68% | -12.454M 6.04% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -15.599M -9.80% | -15.747M -5.32% | -14.224M 2.89% | -13.658M 6.43% | -11.002M 29.47% | -11.057M 29.79% | -10.965M 22.91% | -9.571M 29.92% | -11.179M -1.61% | -11.24M -1.66% | -9.394M 14.33% | -7.538M 21.24% |
All data in USD
14 analysts have analysed CBLL and the average price target is 28.41 USD. This implies a price increase of 53.01% is expected in the next year compared to the current price of 18.57.
CERIBELL INC (CBLL) will report earnings on 2026-05-06.
The consensus EPS estimate for the next earnings of CERIBELL INC (CBLL) is -0.4 USD and the consensus revenue estimate is 26.61M USD.
The consensus rating for CERIBELL INC (CBLL) is 88.5714 / 100 . This indicates that analysts generally have a positive outlook on the stock.